Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Want to cut your energy bills? Here’s how five experts are doing it 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 08, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced the appointment of Elizabeth Howard, Ph.D., J.D. as Executive Vice President and General Counsel.
“We are delighted to welcome Liz to the Arbutus team. Her legal and business experience will be invaluable to Arbutus as we reinforce our position as a leading HBV solutions company. Over the past decade Arbutus, with support from Liz as external counsel, has established a dominant position in LNP technology including key patents, knowhow and manufacturing trade secrets which we are applying to our HBV franchise as well as existing and prospective partnerships,” said Dr. Mark J. Murray, Arbutus' President and CEO. "In addition, Arbutus has been building intellectual property around our proprietary HBV product candidates and scientific discoveries. Liz’s addition to the team will further bolster our initiatives to maintain and grow our strong intellectual property as well as other legal and business matters.”
Dr. Howard joins Arbutus from Orrick, where she was an intellectual property partner and co-chaired Orrick’s life sciences practice. Dr. Howard focused on patent infringement litigation, with an emphasis on the life sciences. Dr. Howard holds a B.A. with honors from the University of California, Santa Barbara, a Ph.D. in Molecular Biology from the University of California, Berkeley, and a J.D. from the University of California, Hastings College of the Law.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Our strategy is to target the three pillars necessary to develop a curative regimen for HBV: suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA that is the source of HBV persistence. Our portfolio of assets includes a broad pipeline of drug candidates for use in combination to develop a cure for HBV. To support continuous discovery of potential novel drug candidates and technologies, Arbutus has a research collaboration agreement with the Baruch S. Blumberg Institute that provides exclusive rights to in-license any intellectual property generated through the collaboration. The Baruch S. Blumberg Institute was established in 2003 by the Hepatitis B Foundation.
Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: [email protected] Helia Baradarani Manager, Investor Relations Phone: 604.419.3200 Email: [email protected] Media Please direct all media inquiries to: [email protected]
